CN110951883A - Application of LINCR-0001 in preparation of gastric cancer diagnosis product and treatment medicine - Google Patents

Application of LINCR-0001 in preparation of gastric cancer diagnosis product and treatment medicine Download PDF

Info

Publication number
CN110951883A
CN110951883A CN201911399590.9A CN201911399590A CN110951883A CN 110951883 A CN110951883 A CN 110951883A CN 201911399590 A CN201911399590 A CN 201911399590A CN 110951883 A CN110951883 A CN 110951883A
Authority
CN
China
Prior art keywords
gastric cancer
lincr
coding rna
seq
long non
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201911399590.9A
Other languages
Chinese (zh)
Inventor
杨承刚
陈丽媛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Yangshen Biomedical Co Ltd
Original Assignee
Beijing Medintell Bioinformatic Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Medintell Bioinformatic Technology Co Ltd filed Critical Beijing Medintell Bioinformatic Technology Co Ltd
Priority to CN201911399590.9A priority Critical patent/CN110951883A/en
Publication of CN110951883A publication Critical patent/CN110951883A/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Abstract

The invention belongs to the field of genetic engineering, and particularly relates to application of LINCR-0001 in preparation of gastric cancer diagnosis products and treatment medicines. In addition, the invention also relates to related primers and a diagnostic kit thereof. The relation between the long-chain non-coding RNA and the pathogenesis of gastric cancer is revealed by researching the expression of the long-chain non-coding RNA at the cellular level.

Description

Application of LINCR-0001 in preparation of gastric cancer diagnosis product and treatment medicine
Technical Field
The invention belongs to the field of biomedicine, and relates to application of LINCR-0001 in preparation of gastric cancer diagnosis products and treatment medicines.
Background
Gastric Cancer (GC) is the second largest cancer worldwide leading to death. The rapid progression and metastasis of the disease results in a poor prognosis. In order to improve early diagnosis and targeted therapy of GC, understanding of its underlying molecular mechanisms and identifying new, effective biomarkers and therapeutic targets are urgently needed.
Long-chain non-coding RNAs (lncrnas) are RNA molecules with transcripts longer than 200nt, different from other small-molecule non-coding RNAs, which can regulate RNA metabolism, protein functional activity, histone modification and chromatin remodeling in a cis (in cis) or trans (in trans) action manner, and are widely involved in cellular biological processes at epigenetics, transcription and post-transcriptional levels. Non-coding RNA (ncrna) is RNA that cannot be translated into protein. Two main categories are distinguished: small RNAs (< 200NT) and lncRNAs. Small ncRNA, including small RNA, siRNA and DNA, has been demonstrated to play an important role in gastric carcinogenesis. In recent years, a number of studies have shown that lncRNAs are involved in the development of a variety of diseases, having a variety of functions in a wide range of biological processes, particularly in connection with the development of human cancer. The study showed that: in addition to these coding genes, which have been extensively studied, abnormal expression of long noncoding RNAs (lncRNAs) is also involved in tumor malignant progression. More and more researches prove that the lncRNAs not only play an important role in maintaining the normal physiological functions and the development process of the body, but also have close relation between the abnormal expression and the occurrence and the development of diseases, particularly the malignant development of tumors. One well-known pathogenesis of tumor involvement of oncogenic lncRNA is HOTAIR (HOX transcriptional antisense RNA), which is consistently up-regulated and is identified as a prognostic marker of patient outcome, e.g., affecting survival in a variety of human tumor patients.
Recently, many studies have shown that lncRNA is highly expressed in gastric cancer tissues. Therefore, there is an urgent need to find new lncRNAs and investigate their biological effects on gastric cancer in order to obtain potential therapeutic targets for diagnosis and gene therapy of gastric cancer.
Disclosure of Invention
The invention aims to provide a long-chain non-coding RNA marker for diagnosing and treating gastric cancer. Experiments prove that the expression level of LINCR-0001 in gastric cancer tissues is obviously higher than that in para-cancer tissues, so that the LINCR-0001 can be used as a molecular marker for diagnosing and treating gastric cancer.
In order to test the purpose, the invention adopts the following technical scheme:
the invention provides an application of a reagent for detecting long-chain non-coding RNA expression in preparation of gastric cancer diagnosis products.
The long-chain non-coding RNA of the invention is named LINCR-0001 in NCBI, and the gene ID: 101929191, the transcript sequence for LINCR-0001 is Genbank accession No. NR _120604.1 (having a length of 545bp, corresponding to the DNA sequence shown in SEQ ID NO. 1).
Further, the reagent comprises a PCR amplification primer used for detecting the expression level of LINCR-0001 by using SYBR Green, a TaqMan probe, a molecular beacon, a double-hybrid probe or a composite probe.
In a specific embodiment of the invention, the primer sequences are shown as SEQ ID NO.2 and SEQ ID NO. 3.
The invention provides a product for gastric cancer diagnosis, which comprises an agent for detecting the expression level of LINCR-0001.
Further, the reagent comprises SYBR Green, a TaqMan probe, a molecular beacon, a double-hybrid probe or a PCR amplification primer used for detecting the expression level of LINCR-0001 by a composite probe.
In a specific embodiment of the invention, the primer sequences are shown as SEQ ID NO.2 and SEQ ID NO. 3.
Further, the aforementioned products include, but are not limited to, chips, kits, test strips, or high throughput sequencing platforms; the high-throughput sequencing platform is a special tool for diagnosing gastric cancer, and with the development of a high-throughput sequencing technology, the construction of an RNA expression profile of a person becomes very convenient work. By comparing the RNA expression profiles of patients with disease and normal populations, it is easy to identify which RNA abnormalities are associated with disease. Therefore, the knowledge that the abnormality of non-LINCR-0001 is associated with gastric cancer in high-throughput sequencing is also included in the use of LINCR-0001 and is also within the scope of the present invention.
The kit comprises a reagent for detecting the expression level of LINCR-0001, wherein the reagent comprises a nucleic acid combined with the LINCR-0001 or a DNA sequence thereof, and the nucleic acid comprises SYBR Green, a TaqMan probe, a molecular beacon, a double-hybrid probe or a PCR amplification primer used when a composite probe is used for detecting the expression level of LINCR-0001.
The chip comprises a reagent for detecting the expression level of LINCR-0001, wherein the reagent comprises a nucleic acid combined with LINCR-0001 or a DNA sequence thereof, and the nucleic acid comprises a probe capable of detecting the expression level of LINCR-0001.
The test strip comprises a reagent for detecting the expression level of LINCR-0001, wherein the reagent comprises a nucleic acid combined with LINCR-0001 or a DNA sequence thereof, and the nucleic acid comprises a probe capable of detecting the expression level of LINCR-0001.
The present invention provides a pharmaceutical composition for treating gastric cancer, comprising an agent that inhibits LINCR-0001.
Further, the agent is not limited as long as it can inhibit the expression level of LINCR-0001 or inhibit the functional activity of LINCR-0001.
The reagent comprises siRNA or shRNA of LINCR-0001. In a specific embodiment of the invention, the siRNA sequence of LINCR-0001 is shown as SEQ ID NO.6 and SEQ ID NO. 7.
The pharmaceutical composition of the present invention may be administered alone or together with other drugs as a medicine. The other drug that can be administered together with the pharmaceutical composition of the present invention is not limited as long as it does not impair the effect of the therapeutic or prophylactic pharmaceutical composition of the present invention.
The pharmaceutical composition of the invention can be prepared into various dosage forms according to requirements. Including, but not limited to, tablets, solutions, granules, patches, ointments, capsules, aerosols or suppositories for transdermal, mucosal, nasal, buccal, sublingual or oral use.
The route of administration of the pharmaceutical composition of the present invention is not limited as long as it can exert the desired therapeutic or prophylactic effect, and includes, but is not limited to, intravenous, intraperitoneal, intraocular, intraarterial, intrapulmonary, oral, intravesicular, intramuscular, intratracheal, subcutaneous, transdermal, transpleural, topical, inhalation, transmucosal, cutaneous, gastrointestinal, intraarticular, intraventricular, rectal, vaginal, intracranial, intraurethral, intrahepatic. In some cases, the administration may be systemic. In some cases topical administration.
The dosage of the pharmaceutical composition of the present invention is not limited as long as the desired therapeutic effect or prophylactic effect is obtained, and can be appropriately determined depending on the symptoms, sex, age, and the like. The dose of the therapeutic or prophylactic pharmaceutical composition of the present invention can be determined using, for example, the therapeutic effect or prophylactic effect on a disease as an index.
The invention also provides the application of the long-chain non-coding RNA in preparing a medicament for treating gastric cancer.
The invention also provides the application of the reagent for inhibiting the long-chain non-coding RNA in preparing the medicine for treating gastric cancer.
Further, the reagent is as defined above.
The present invention also provides a method for diagnosing gastric cancer, comprising the steps of:
(1) obtaining a sample from a subject;
(2) detecting the expression level of LINCR-0001 in the subject sample;
(3) correlating the measured expression level of LINCR-0001 with the presence or absence of disease in the subject.
(4) If the expression level of LINCR-0001 is increased compared to the control, the subject is judged to have gastric cancer, or the subject is at high risk of having gastric cancer, or the gastric cancer patient is judged to have poor prognosis.
The invention also provides a method for treating gastric cancer, which comprises reducing the expression level of LINCR-0001 or inhibiting the functional activity of LINCR-0001.
The present invention also provides a method for screening a gastric cancer drug, which can determine the effect of a tumor drug on improving tumor prognosis by measuring the expression level of LINCR-0001 after adding a test drug to gastric cancer cells or at a certain period after administering the test drug to a gastric cancer model animal. More specifically, when the expression level of LINCR-0001 is decreased or normal level is restored after addition or administration of the test drug, the drug can be selected as a therapeutic drug for improving the prognosis of the tumor.
In the context of the present invention, "diagnosing gastric cancer" includes determining whether a subject has gastric cancer, determining whether a subject is at risk of having gastric cancer, determining responsiveness of a gastric cancer patient to drug treatment, or determining a prognosis for a gastric cancer patient.
As used herein, "treatment" encompasses treatment-related diseases or disease states in a mammal, such as a human, having the associated disease or disorder, and includes:
(1) preventing the occurrence of a disease or condition in a mammal, particularly when the mammal is susceptible to said disease condition but has not been diagnosed as having such a disease condition;
(2) inhibiting a disease or disease state, i.e., preventing its occurrence; or
(3) Alleviating the disease or condition, i.e., causing regression of the disease or condition.
The term "treatment" generally refers to the treatment of a human or animal (e.g., as applied by a veterinarian) wherein some desired therapeutic effect is achieved, e.g., inhibiting the progression of a condition (including slowing the progression, stopping the progression), ameliorating the condition, and curing the condition. Treatment as a prophylactic measure (e.g., prophylaxis) is also included. The use of a patient who has not yet developed a condition but who is at risk of developing the condition is also encompassed by the term "treatment".
The invention has the advantages and beneficial effects that:
the invention discloses a molecular marker for diagnosing gastric cancer, which can be used for judging the early stage of gastric cancer occurrence and provides the survival rate of patients.
The therapeutic agent comprising an agent inhibiting LINCR-0001 of the present invention can be used as a novel therapeutic agent for gastric cancer.
Drawings
FIG. 1 shows a statistical graph of the detection of LINCR-0001 expression in gastric cancer tissue using QPCR;
FIG. 2 shows a statistical graph of the inhibition of LINCR-0001 expression using QPCR.
Detailed Description
The present invention will be described in further detail with reference to the accompanying drawings and examples. The following examples are intended to illustrate the invention only and are not intended to limit the scope of the invention. Experimental procedures without specific conditions noted in the examples, generally following conventional conditions, such as Sambrook et al, molecular cloning: the conditions described in the laboratory Manual (New York: Cold Spring harbor laboratory Press,1989), or according to the manufacturer's recommendations.
Example 1 study of differential expression of LncRNA
1. Study object
Surgical specimens (gastric cancer tissues and corresponding paracancerous normal tissues) of 50 primary gastric cancer patients subjected to gastric carcinoma radical surgery in tumor surgery in hospitals were collected. 30 men and 20 women in 50 patients; the patients are 38-79 years old, and the average age is 61 years old, and the patients have not received adjuvant treatment before operation. Immediately storing the tissue specimen at-80 ℃ after RNA extraction.
Grouping standard: a. primary gastric cancer is diagnosed before operation, and the cancer is not treated; b. no other malignancies were merged; c. no other complications such as gastric perforation, gastrointestinal hemorrhage, gastrointestinal obstruction and the like exist, and the general condition of the patient before the operation is good; d. no other chronic diseases, such as hypertension, diabetes, etc.
2. Detection at the transcriptional level
Total RNA was extracted from each of the experimental group (gastric cancer tissue) and the control group (adjacent normal stomach tissue) using RNAassoplus (TaKaRa, Shiga, Japan), and the concentration and purity of the RNA were measured using a spectrophotometer. It was reverse-transcribed into complementary DNA (cDNA) using PrimeScript reverse transcriptase (TaKaRa, Shiga, Japan). cDNA as template, according to SYBRGREEN EX TaqTM(TaKaRa, Shiga, Japan) Specification requires the reaction system and reaction time to carry out QPCR on LightCycler480, and all experimental results were repeated 3 times with results of 2－△△CTAnd calculating and carrying out statistical analysis. GAPDH was used as the reference gene in the experiment. An upstream primer 5'-AGAGTGATGAAGACAACA-3' (SEQ ID NO.2) and a downstream primer 5'-TCCAGATGATTATGACCTT-3' (SEQ ID NO.3) for LINCR-0001; GAPDH upstream primer: 5'-TCATGGGTGTGAACCATGAGAA-3' (SEQ ID NO.4), and a downstream primer 5'-GGCATGGACTGTGGTCATGAG-3' (SEQ ID NO. 5).
3. Results
The statistical results are shown in figure 1, the expression level of LINCR-0001 in the gastric cancer tissue is significantly increased, about 1.9 times, compared with the tissue beside the cancer, and the difference has statistical significance (P < 0.05). Using the GEO database for electronic validation, ROC curve analysis showed that LINCR-0001 when differentiating between gastric cancer patients and normals had an AUC value of 0.8192.
Example 2 inhibition of LINCR-0001 expression
1. Cell culture and transfection
Cell culture: the gastric cancer cell line BGC-823 is prepared from DMEM containing 10% FBS and placed in 5% CO2And saturated humidity, and culturing in a carbon dioxide incubator at 37 ℃. The culture medium was changed every two days and the cells were passaged by digestion with 0.25% trypsin.
siRNA transfection: the day before transfection, cells are digested and plated onto a petri dish or plate in an amount that ensures a density of 30-50% at the next day of transfection. The siRNA transfection was performed strictly according to LipofectaminTM2000, the culture was continued for 48h after 4-6h by replacing fresh culture medium containing 10% FBS.
2. SiRNA design
Design of sirna (smallnterfering rna): through BLAST search, siRNA sequence was designed in the specific sequence region of LINCR-0001:
siRNA-LINCR-0001
sense strand: 5'-AGCAAUUUCUUCAUAAUGGCA-3' (SEQ ID NO. 6);
antisense strand: 5'-CCAUUAUGAAGAAAUUGCUGU-3' (SEQ ID NO. 7).
The above siRNA was synthesized by Shanghai Jima pharmaceutical technology, Inc., while the company provided negative control siRNA (siRNA-NC).
3. Detection of siRNA interference Using QPCR assay
The procedure is as in example 1.
4. Results
After siRNA transfects gastric cancer cell strain BGC823, change of LncRNA transcription level is detected by QPCR. The results are shown in FIG. 2, the expression level of LncRNA in the experimental group cell (siRNA-LncRNA) is obviously reduced compared with the control group cell (siRNA-NC), the inhibition rate is about 84%, the difference has statistical significance (P <0.05), and the result shows that the siRNA-LncRNA of the invention can obviously inhibit the expression of LINCR-0001 in the cell.
Example 3 measurement of ability to inhibit LINCR-0001 expression to proliferate gastric cancer cells
1. The method comprises the following steps:
BGC-823 cells in logarithmic growth phase are taken and inoculated on a 96-well culture plate, after the cells are cultured for 12 hours, siRNA-LncRNA and siRNA-NC are transfected respectively, and after 4-6 hours, DMEM containing 10% FBS is replaced to continue culturing for 72 hours; and adding 10 mu LCCK8 to each well of each plate, incubating for 2h in an incubator, and detecting the absorbance value with the wavelength of 450nm by using a microplate reader. Each group of cells was set with 5 replicate wells, and the experiment was repeated 3 times to plot cell growth curves.
2. Statistical analysis
The experimental data are expressed as mean-squared-off standard deviations (MS-SD) using SPSS15.0 statistical software, and subjected to one-way analysis of variance (ANOVA) or t-test. P <0.05 is statistically significant for the differences.
3. Results
The results showed that 72h after transfection, the cell growth rate of siRNA-LncRNA group (1.022. + -. 0.047) was significantly decreased compared to siRNA-NC (1.546. + -. 0.052) (P < 0.05). The result shows that the inhibition of the expression of LINCR-0001 has an inhibition effect on the proliferation capacity of a gastric cancer cell strain BGC 823.
The above description of the embodiments is only intended to illustrate the method of the invention and its core idea. It should be noted that, for those skilled in the art, without departing from the principle of the present invention, several improvements and modifications can be made to the present invention, and these improvements and modifications will also fall into the protection scope of the claims of the present invention.
Sequence listing
<110> Beijing, the deep biometric information technology GmbH
Application of LINCR-0001 in preparation of gastric cancer diagnosis product and treatment drug
<160>7
<170>SIPOSequenceListing 1.0
<210>1
<211>545
<212>DNA
<213> human source (Homo sapiens)
<400>1
cttggagagg actcaggcta aaagtggcaa gctacttcca agttccaggt gacccatagg 60
ctgtgatgtt gccattatga agaaattgct gtgctcatca acttactttg aaccaagctg 120
ttctttaccg aatgccctga agtcattgga aagtcacact accttgcttt aaagtgaaga 180
attagaattg tttctctgaa gatgagggag gtgcatgaag gatgtcaggt acaacagtgc 240
cgtgtgtatg ctattgagaa ctggacggga gtgaaagaga gtgatgaaga caacagtcta 300
tacagcatct cctattacct gttagctcag tgcttcatgt gcattacctc actgaattct 360
cgcaacagcc caaaaaggtc ataatcatct ggagagacac attggcagag agactacctt 420
aatacaatgg gaggaagcga tgaacaaact gcggtgcatt cacacaacag cggtgctaca 480
cagcagcgaa gaggagcagc cgactgacac gcacaacaac tcggatctca ggagcatcgc 540
accga 545
<210>2
<211>18
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>2
agagtgatga agacaaca 18
<210>3
<211>19
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>3
tccagatgat tatgacctt 19
<210>4
<211>22
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>4
tcatgggtgt gaaccatgag aa 22
<210>5
<211>21
<212>DNA
<213> Artificial Sequence (Artificial Sequence)
<400>5
ggcatggact gtggtcatga g 21
<210>6
<211>21
<212>RNA
<213> Artificial Sequence (Artificial Sequence)
<400>6
agcaauuucu ucauaauggc a 21
<210>7
<211>21
<212>RNA
<213> Artificial Sequence (Artificial Sequence)
<400>7
ccauuaugaa gaaauugcug u 21

Claims (10)

1. The application of the reagent for detecting the expression of the long-chain non-coding RNA in the preparation of gastric cancer diagnosis products; the long non-coding RNA is LINCR-0001.
2. The use of claim 1, wherein the reagent comprises PCR amplification primers used for detecting the expression level of the long non-coding RNA by using SYBR Green, TaqMan probes, molecular beacons, two-hybrid probes, or composite probes.
3. The use according to claim 2, wherein the primer sequences are shown as SEQ ID No.2 and SEQ ID No. 3.
4. The use according to any one of claims 1 to 3, wherein the product comprises a kit, chip, or strip.
5. A product for gastric cancer diagnosis comprising an agent for detecting the expression of the long non-coding RNA of any one of claims 1 to 4.
6. The product of claim 5, wherein the reagent comprises SYBR Green, TaqMan probes, molecular beacons, two-hybrid probes, or PCR amplification primers used in the detection of the expression level of the long non-coding RNA.
7. The product of claim 6, wherein the primer sequences are shown as SEQ ID No.2 and SEQ ID No. 3.
8. A pharmaceutical composition for treating gastric cancer, comprising an agent that inhibits the long non-coding RNA of any one of claims 1-4.
9. The pharmaceutical composition of claim 8, wherein the agent comprises an agent that inhibits the level of the long non-coding RNA or an agent that inhibits the functional activity of the long non-coding RNA.
10. Use of the long non-coding RNA of any one of claims 1-4 in the manufacture of a medicament for the treatment of gastric cancer.
CN201911399590.9A 2019-12-30 2019-12-30 Application of LINCR-0001 in preparation of gastric cancer diagnosis product and treatment medicine Withdrawn CN110951883A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911399590.9A CN110951883A (en) 2019-12-30 2019-12-30 Application of LINCR-0001 in preparation of gastric cancer diagnosis product and treatment medicine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911399590.9A CN110951883A (en) 2019-12-30 2019-12-30 Application of LINCR-0001 in preparation of gastric cancer diagnosis product and treatment medicine

Publications (1)

Publication Number Publication Date
CN110951883A true CN110951883A (en) 2020-04-03

Family

ID=69984961

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911399590.9A Withdrawn CN110951883A (en) 2019-12-30 2019-12-30 Application of LINCR-0001 in preparation of gastric cancer diagnosis product and treatment medicine

Country Status (1)

Country Link
CN (1) CN110951883A (en)

Similar Documents

Publication Publication Date Title
Wei et al. miR-532-5p is a prognostic marker and suppresses cells proliferation and invasion by targeting TWIST1 in epithelial ovarian cancer.
US20170073775A1 (en) Compositions and methods for prognosis of ovarian cancer
CN108531596B (en) Application of lncRNA as biomarker in diagnosis and treatment of gastric cancer
CN108559779B (en) Long-chain non-coding RNA as diagnosis and treatment marker of gastric cancer
Xin et al. Up-regulated circular RNA hsa_circ_0067934 contributes to glioblastoma progression through activating PI3K-AKT pathway.
CN113462780B (en) Marker and kit for auxiliary diagnosis of prostate cancer
Cui et al. LncRNA HOXA-AS2 regulates microRNA-216a-5p to promote malignant progression of non-small cell lung cancer.
Xiao et al. miR-130b regulates the proliferation, invasion and apoptosis of glioma cells via targeting of CYLD
CN108504658B (en) Application of LINC01836 in preparation of gastric cancer diagnosis products and treatment medicines
CN111304326B (en) Reagent for detecting and targeting lncRNA biomarker and application of reagent in hepatocellular carcinoma
WO2013148151A1 (en) Plasma microribonucleic acids as biomarkers for endometriosis and endometriosis-associated ovarian cancer
CN112322741A (en) Application of biomarker RP11-54A9.1 in prediction of oral squamous cell carcinoma and treatment thereof
CN107058480B (en) Long-chain non-coding RNA marker for diagnosing adenocarcinoma of lung
CN111647660B (en) Application of Linc01559 in diagnosis and treatment of gastric cancer
CN111518913B (en) Non-coding RNA-LINC01819 for diagnosis and treatment of gastric cancer
Ni et al. MicroRNA-30c suppressed giant-cell tumor of bone cell metastasis and growth via targeting HOXA1.
CN106906290B (en) CDSN as diagnosis and treatment target of tongue squamous cell carcinoma
CN110923326A (en) Application of LINC01909 in preparation of cancer treatment drug and diagnostic kit
CN111088355A (en) Molecular marker and kit for gastric cancer diagnosis
CN110951881A (en) Novel approach for diagnosis and treatment of gastric cancer
CN110923324A (en) Breast cancer miRNA marker and application thereof
Chen et al. LncRNA LINP1 promotes malignant progression of pancreatic cancer by adsorbing microRNA-491-3p.
CN110951883A (en) Application of LINCR-0001 in preparation of gastric cancer diagnosis product and treatment medicine
CN111733248B (en) Application of LOC158435 as biomarker for diagnosing and treating laryngeal squamous cell carcinoma
CN110904240A (en) Application of LINC00884 as cancer diagnosis and treatment marker

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20200323

Address after: Room 2503, Qianshan building, building D2, Qingdao International Innovation Park Phase II, No. 1, Keyuan Weiyi Road, Laoshan District, Qingdao, Shandong Province

Applicant after: Qingdao Yangshen biomedical Co.,Ltd.

Address before: Room 1210, Building 3, Ronghua Xintai Building, 10 Ronghua South Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing

Applicant before: BEIJING MEDINTELL BIOMED Co.,Ltd.

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20200403